NCT07110675Completed
Central Sensitisation in Patients With Haemophilia and Degenerative Arthropathy
Identification of Central Sensitisation in Patients With Haemophilia and Degenerative Arthropathy of the Lower Limbs. A Cross-sectional Cohort Study
Source: ClinicalTrials.gov · Last updated 20 Feb 2026
Brief summary (registry, in English)
Introduction: Hemophilic arthropathy is characterized by functional impairments, disabling physical sequelae, and chronic pain. Central pain sensitization describes increased neural excitability characterized by spontaneous or persistent pain, increased pain areas, allodynia, and hyperalgesia. Objectives: To evaluate central pain sensitization in patients with hemophilia and degenerative knee and ankle arthropathy and to identify the best predictive model of central pain sensitization in these patients. Methods: Multicenter cross-sectional cohort study. Eighty-six patients with hemophilic knee and ankle arthropathy will be recruited through the Spanish Hemophilia Federation. The primary outcome measure will be central pain sensitization (Central Sensitization Inventory), with age as the dependent variable. The secondary variables will be kinesiophobia (Tampa Scale for Kinesiophobia), catastrophizing (Pain Catastrophizing Scale), and pain anxiety (Pain Anxiety Symptoms Scale-20). The variables estimated as modifiers or confounders will be pain intensity (Visual Analogue Scale), joint status (Hemophilia Joint Health Score), severity and type of hemophilia, development of inhibitors, and sociodemographic variables. Expected results: To identify the degree of central pain sensitization in patients with hemophilic arthropathy. To identify the best predictive model for central pain sensitization in these patients based on the study variables.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 146 (actual)
- First submitted
- 25 Jul 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 28 Oct 2025
- Lead sponsor
- Investigación en Hemofilia y Fisioterapia
- Diseases
- Haemophilia
- NCT number
- NCT07110675
What you commit to
- Study type: Observational
- Participants enrolled: 146
- From 1 Aug 2025 to the primary completion date, 28 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have had ankle or knee haemarthrosis in the 6 months prior to the start of the study.
- Patients who have taken analgesic or anti-inflammatory drugs in the 10 days prior to the study.
Other
- Patients with neurological or cognitive impairments that prevent them from understanding the questionnaires and physical tests.
- Patients who are undergoing an intervention (physiotherapy or orthopaedic) at the time of the study.
Who the study is looking for
- Patients diagnosed with haemophilia A and B.
- Over 35 years of age.
- With a medical diagnosis of bilateral haemophilic ankle arthropathy.
- With a clinical assessment using the Hemophilia Joint Health Score greater than 4 points.
- On prophylactic treatment with FVIII/FIX coagulation concentrates or monoclonal antibodies.
- Sign the informed consent document.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universidad de Oviedo Coordinator of this site? Confirm its status | Oviedo | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.